Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Anna Turkina, Tommy Fu, Vivian G. Oehler, Hengbang Wang et al.
Citations
22 citations
Journal
JAMA Oncology
Topics
Chronic Myeloid Leukemia Treatments
Field-Weighted Citation Impact (FWCI)
10.00
article
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
Anna Turkina, Tommy Fu, Vivian G. Oehler, Hengbang Wang, Jörge E. Cortes, Svetlana Samarina, Anthony Michael Hunter, Yifan Zhai, Omer Jamy, Lixin Jiang, Vera Zherebtsova, Huanshan Guo, Maria R. Baer, Cunlin Wang, Olga Uspenskaya, Paul Koller, Vasily Shuvaev, Elza Lomaia, И. Л. Давыдкин, Dajun Yang, Zi Chen, Sudipto Mukherjee, Elias Jabbour, H. Kantarjian
article en
22 citations
Abstract
No abstract available for this paper.
Publication Tag
JAMA OncologyVol. 11(1)
Institutions
University of Maryland, Baltimore (US), City Of Hope National Medical Center (US), Cleveland Clinic (US), The University of Texas MD Anderson Cancer Center (US), Emory University (US), Sun Yat-sen University (CN), Federal Almazov North-West Medical Research Centre (RU), University of Alabama at Birmingham (US), Augusta University Health (US), Fred Hutch Cancer Center (US), Leningrad Regional Cancer Center (RU), National Medical Research Center for Hematology (RU), Kirov Research Institute of Hematology and Blood Transfusion FMBA (RU), Medical Radiological Research Center (RU), Botkin Hospital (RU), Samara State Medical University (RU), City Clinical Hospital (RU), Sun Yat-sen University Cancer Center (CN), U-M Rogel Cancer Center (US)